According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.

A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...

Learn the symptoms of bladder cancer —blood in the urine, pain, and irritation or obstruction when urinating —and when to see a healthcare provider.

The LEGEND trial showed a 62% complete response (CR) rate with the non-viral gene therapy at six months in NMIBC patients who ...

The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...

Minze Health announced that it entered into a three-year agreement with Medtronic to commercialize its overactive bladder ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...